ARTICLE | Company News
Affymax, Takeda Hematide deal
February 14, 2006 2:31 AM UTC
Affymax (Palo Alto, Calif.) granted Takeda (Tokyo:4502) exclusive rights to develop and commercialize Hematide for anemia in Japan. Takeda will pay Affymax $17 million up front and purchase $10 millio...